Interferon beta 1b (Betaseron, BAY86-5046)
( DrugBank: - / KEGG DRUG: - )
1 disease
告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
13 | 多発性硬化症/視神経脊髄炎 | 23 |
13. 多発性硬化症/視神経脊髄炎
臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
Showing 1 to 10 of 23 trials
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT02652091 (ClinicalTrials.gov) | February 5, 201620160205 | 5/1/201620160105 | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction | Multiple Sclerosis, Relapsing-Remitting | Drug: Interferon beta-1b (Betaseron, BAY86-5046);Device: BETACONNECT device | Bayer | NULL | Completed | 18 Years | N/A | All | 146 | United States | |
2 | NCT01706055 (ClinicalTrials.gov) | September 201220120900 | 7/9/201220120907 | Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment ... | Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon® Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment ... | Multiple Sclerosis | Biological: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | All | 629 | N/A | Poland |
3 | NCT01491100 (ClinicalTrials.gov) | April 30, 201220120430 | 12/12/201120111212 | Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple S ... | Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS Under Treatment With Betaferon® Study Assessing Cognitive Performance Plus Physical Activity in Patients With Relapsing-Remitting MS ... | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 12 Years | 70 Years | All | 1085 | Albania;Algeria;Argentina;Belgium;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Kazakhstan;Netherlands;Portugal;Saudi Arabia;Tunisia;Turkey;Bosnia and Herzegovina;Czech Republic;Jordan;Lebanon;Mexico;Poland;Syrian Arab Republic Albania;Algeria;Argentina;Belgium;Czechia;Egypt;France;Germany;Greece;Hungary;Israel;Kazakhstan;Neth ... | |
4 | NCT01436838 (ClinicalTrials.gov) | March 201220120300 | 19/9/201120110919 | China Betaferon Adherence, Coping and Nurse Support Study | Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin ... | Multiple Sclerosis, Chronic Progressive | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | 75 Years | Both | 110 | N/A | China |
5 | NCT01076595 (ClinicalTrials.gov) | May 201020100500 | 25/2/201020100225 | Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years ... | Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associat ... | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | Both | 73 | N/A | France |
6 | NCT00963833 (ClinicalTrials.gov) | December 17, 200920091217 | 21/8/200920090821 | Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis | Study Evaluating Betaferons® Safety and Tolerability In Pediatric Patients With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 12 Years | 16 Years | All | 68 | N/A | Austria;Belgium;Finland;Germany;Israel;United Kingdom;Italy;Portugal |
7 | NCT00902135 (ClinicalTrials.gov) | May 200920090500 | 13/5/200920090513 | Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH) Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Relate ... | Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Supported Effects on Adherence to a Long-term Injection Therapy (BETAPATH) Betaferon® Injection Management: Non-interventional Study on Personal Digital Assistant (PDA)Support ... | Relapsing-Remitting Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | Both | 702 | N/A | Germany |
8 | NCT03408093 (ClinicalTrials.gov) | February 3, 200920090203 | 8/1/201820180108 | Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b | Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Tr ... | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | 100 Years | All | 120 | NULL | |
9 | NCT01184833 (ClinicalTrials.gov) | September 200820080900 | 18/8/201020100818 | Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients S ... | Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Patients With Relapsing Forms of Multiple Sclerosis Evaluation of Risk Factors for Premature Discontinuation of Injection Treatment With Betaferon in Pa ... | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, BAY86-5046) | Bayer | NULL | Completed | 18 Years | N/A | Both | 852 | N/A | Poland |
10 | NCT03577977 (ClinicalTrials.gov) | June 1, 200820080601 | 25/6/201820180625 | Betaferon Use in Children and Adolescents With Multiple Sclerosis | Retrospective Data Collection on Betaferon Use in Children and Adolescents With Multiple Sclerosis | Multiple Sclerosis | Drug: Interferon beta-1b (Betaseron, Betaferon, BAY86-5046) | Bayer | NULL | Completed | N/A | 18 Years | All | 70 | Russian Federation |